1. Home
  2. RIGL vs CMDB Comparison

RIGL vs CMDB Comparison

Compare RIGL & CMDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • CMDB
  • Stock Information
  • Founded
  • RIGL 1996
  • CMDB 2023
  • Country
  • RIGL United States
  • CMDB Monaco
  • Employees
  • RIGL N/A
  • CMDB N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • CMDB
  • Sector
  • RIGL Health Care
  • CMDB
  • Exchange
  • RIGL Nasdaq
  • CMDB Nasdaq
  • Market Cap
  • RIGL 335.5M
  • CMDB 291.4M
  • IPO Year
  • RIGL 2000
  • CMDB N/A
  • Fundamental
  • Price
  • RIGL $30.17
  • CMDB $14.62
  • Analyst Decision
  • RIGL Buy
  • CMDB
  • Analyst Count
  • RIGL 5
  • CMDB 0
  • Target Price
  • RIGL $38.20
  • CMDB N/A
  • AVG Volume (30 Days)
  • RIGL 668.8K
  • CMDB 85.6K
  • Earning Date
  • RIGL 11-06-2025
  • CMDB 11-12-2025
  • Dividend Yield
  • RIGL N/A
  • CMDB N/A
  • EPS Growth
  • RIGL N/A
  • CMDB N/A
  • EPS
  • RIGL 5.43
  • CMDB N/A
  • Revenue
  • RIGL $267,921,000.00
  • CMDB $799,159,000.00
  • Revenue This Year
  • RIGL $59.93
  • CMDB N/A
  • Revenue Next Year
  • RIGL N/A
  • CMDB N/A
  • P/E Ratio
  • RIGL $5.32
  • CMDB N/A
  • Revenue Growth
  • RIGL 105.62
  • CMDB 152.53
  • 52 Week Low
  • RIGL $13.57
  • CMDB $8.46
  • 52 Week High
  • RIGL $43.72
  • CMDB $14.97
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 39.94
  • CMDB N/A
  • Support Level
  • RIGL $27.75
  • CMDB N/A
  • Resistance Level
  • RIGL $29.46
  • CMDB N/A
  • Average True Range (ATR)
  • RIGL 1.49
  • CMDB 0.00
  • MACD
  • RIGL -0.41
  • CMDB 0.00
  • Stochastic Oscillator
  • RIGL 25.90
  • CMDB 0.00

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About CMDB Costamare Bulkers Holdings Limited Common Stock

Costamare Bulkers Holdings Ltd is an international owner and operator of dry bulk vessels providing multinational transportation of dry bulk commodities for a broad range of customers. Its owned fleet consists of 38 vessels, with a total carrying capacity of approximately 3,017,000 dwt. The company's vessels transport a broad range of bulks across the shipping routes around the world. Iron ore, coal and grain constitute the majority of its cargoes.

Share on Social Networks: